$0.61
9.06%
Nasdaq, Nov 28, 09:57 pm CET
ISIN
US05479K1060
Symbol
ELUT

Aziyo Biologics Inc - Ordinary Shares - Class A Stock price

$0.61
-0.28 31.71% 1M
-1.11 64.42% 6M
-3.13 83.64% YTD
-3.58 85.39% 1Y
-6.41 91.28% 3Y
-13.34 95.61% 5Y
-16.39 96.40% 10Y
-16.39 96.40% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.06 9.06%
ISIN
US05479K1060
Symbol
ELUT
Industry

Key metrics

Basic
Market capitalization
$26.1m
Enterprise Value
$47.5m
Net debt
$21.4m
Cash
$4.7m
Shares outstanding
42.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.2 | 1.1
EV/Sales
2.3 | 1.9
EV/FCF
-
P/B
negative
Financial Health
Equity Ratio
-128.1%
Return on Equity
116.6%
ROCE
179.5%
ROIC
187.4%
Debt/Equity
-0.6
Financials (TTM | estimate)
Revenue
$21.1m | $24.8m
EBITDA
- | $-13.8m
EBIT
$-21.4m | $-29.9m
Net Income
$-26.5m | $-27.0m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
-33.0% | 1.9%
EBITDA
- | 33.9%
EBIT
11.0% | -23.3%
Net Income
51.2% | 49.9%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
46.0%
EBITDA
- | -55.4%
EBIT
-101.5%
Net
-125.6% | -108.8%
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
-
Short interest
0.2%
Employees
51
Rev per Employee
$480.0k
Show more

Is Aziyo Biologics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Aziyo Biologics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

Buy
88%
Hold
13%

Financial data from Aziyo Biologics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
21 21
33% 33%
100%
- Direct Costs 11 11
20% 20%
54%
9.69 9.69
27% 27%
46%
- Selling and Administrative Expenses 27 27
12% 12%
127%
- Research and Development Expense 4.28 4.28
22% 22%
20%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -21 -21
11% 11%
-101%
Net Profit -26 -26
51% 51%
-126%

In millions USD.

Don't miss a Thing! We will send you all news about Aziyo Biologics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aziyo Biologics Inc - Ordinary Shares - Class A Stock News

Neutral
Seeking Alpha
24 days ago
Elutia Inc. ( ELUT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants C. Mills - Co-Founder, President, CEO & Director Matthew Ferguson - Chief Financial Officer Conference Call Participants Matt Steinberg Junwoo Park - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, everyone, and welcome to Elutia Third Quarter 2025 Financial Results Call.
Neutral
GlobeNewsWire
25 days ago
- Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m.
Neutral
GlobeNewsWire
about one month ago
GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern...
More Aziyo Biologics Inc - Ordinary Shares - Class A News

Company Profile

Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded on August 6, 2015 and is headquartered in Silver Spring, MD.

Head office United States
CEO Charles Mills
Employees 51
Founded 2015
Website elutia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today